P. Bliss et al., AN ASSESSMENT OF THE CLINICAL USEFULNESS OF 2 SERUM MARKERS, CA 15 3 AND HMFG 2 IN LOCALIZED AND METASTATIC BREAST-CANCER, Disease markers, 11(1), 1993, pp. 45-48
CA 15 3 is a circulating glycoprotein defined by two monoclonal antibo
dies (115 D 8 and DF 3) with good specificity for breast cancer. Tumou
r-associated antigens have been detected by the monoclonal antibody HM
FG 2 using a low pH ELISA method. We compare the values obtained using
these two assays in patients with localized and metastatic breast can
cer. CA 15 3 and HMFG 2 levels were measured in 61 patients, 24 locali
zed and 37 metastatic, evaluated by standard biochemical and radiologi
cal testing. Of the patients with metastatic disease 78.4 per cent had
an elevated CA 15 3 level whereas only 8.3 per cent of patients with
localized disease had an elevated level (chi2 = 28.2 p = 0.001); 29.8
per cent of patients with metastatic discase had elevated HMFG 2 level
s while among those with localized disease 16.7 per cent had elevated
levels (chi2 = 0.57 p = NS). We conclude that only CA 15 3 is a useful
marker in advanced disease.